Abstract:4596 Background: Recently clinical trials like BLASST-1 and SAKK06/17 showed that immunotherapy combined with chemotherapy as neoadjuvant regimen of muscle-invasive bladder cancer (MIBC)may produce synergistic effects with good tolerability. Toripalimab, a PD-1 inhibitor, has achieved good therapeutic effects in advanced urothelial cancer. This clinical study was designed to verify the safety and efficacy of Toripalimab with gemcitabine-cisplatin (GC) as neoadjuvant therapy (NAT) for MIBC. Methods: It is a prospective, single-arm, open-label, single-center phase II clinical study from China (ChiCTR2100051298). Thirty patients with MIBC clinically staged as T2-3b N0 M0, who were scheduled for RC were enrolled. Patients received: Toripalimab 240 mg + Gemcitabine 1000 mg/m2 + Cisplatin 70mg/m2 on day 1, Gemcitabine 1000mg/m2 on day 8 every 21 days (1 cycle), totally for 4 cycles. RC will be performed 1 month after last therapy. The primary endpoint is pathological complete response (pCR), and the secondary endpoints are safety, overall survival (OS), and progression-free survival (PFS). The tumor regression effect after NAT will be evaluated by comparing the postoperative pathological results with the preoperative radiological results. The FISHER's exact test was used to analyze the relationship between genomic changes / tumor mutation burden (TMB) and pCR rate. This study has been approved by the Ethics Committee of Gulou Hospital, Nanjing. Results: From Jan 2020 to Dec 2021, 30 individuals participated in the study and received at least 1 cycle therapy, and 3 dropped out before RC. Among the patients who underwent RC, the pathological response (PaR) rate was 63% (17/27) and the pCR rate was 40.7% (11/27). The 1-year and 3-year PFS rates are 85.2% and 77.6%, respectively; The 1-year and 3-year OS rates are 96.2% and 84.6%, respectively. In the patients with PD-L1 expression ≥5% (n = 16), pCR and PaR rates was 43.8% (7/16) and 68.8% (11/16), respectively. In the patients with PD-L1 expression < 5% (n = 11), the pCR rate was 36.4% (4/11) and the PaR rate was 63.6% (7/11). The status of PD-L1 expression and TMB were not associated with pCR rate. Further biomarker analysis indicated that patients with any dual co-mutation in KMT2D/ERBB2/EPHA2 were associated with a lower pCR rate. Among the 30 patients, 24 cases (80%) experienced treatment related adverse reactions (AEs), with no grade 4 AEs nor above. Two patients experienced grade 3 AEs, including thrombocytopenia (1) and proteinuria (1). The most common AEs were pruritus (33.3%), fatigue (26.7%), and nausea (23.3%). Nine cases (30%) experienced immune-related AEs, including rash, thyroid dysfunction, increased blood glucose, and pneumonia, with no grade 3-4 AEs. Conclusions: Toripalimab combined with GC chemotherapy demonstrates good efficacy and tolerability and is an alternative option for NAT of MIBC. Clinical trial information: ChiCTR2100051298.

A Phase II Clinical Trial of Toripalimab Combined with Cisplatin Plus Gemcitabine Chemotherapy As Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer.

A phase II study of toripalimab combined with gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC).

Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.

Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.

Interim results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy for patients with cT2-T4aN0M0 MIBC.

Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial

A Multi-Center Phase II Study of Toripalimab with Chemotherapy in Patients with EGFR Mutant Advanced NSCLC Patients Resistant to EGFR TKIs: Efficacy and Biomarker Analysis.

Efficacy and Safety of Neoadjuvant Therapy with Disitamab Vedotin Plus Toripalimab in Treating Muscle Invasive Urothelial Bladder Cancer Followed by Selective Bladder-Preserving or Radical Cystectomy.

Clinical Response and Biomarker Analysis of a Phase II Basket Trial of Toripalimab, a PD-1 Mab in Combination with Standard Chemotherapy As a First-Line Treatment for Patients with Solid Tumors.

2375P Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin (GP) for Muscle-Invasive Bladder Cancer (MIBC) Patients Followed by Selective Bladder Sparing Surgery

Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer

A prospective phase II trial of neoadjuvant sintilimab in muscle-invasive urothelial carcinoma of bladder.

Efficacy and safety analysis of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer

Real-world study of chemotherapy plus immunotherapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer.

Longitudinal Personalized Urinary Tumor DNA Analysis in Muscle-Invasive Bladder Cancer from the Neoadjuvant Immunotherapy Trial RJBLC-I2N003.

703P Camrelizumab in Combination with Gemcitabine Plus Cisplatin As Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer

Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle‐invasive bladder cancer: A multi‐center, single‐arm, phase 2 study

A phase 2, open-label study of neoadjuvant chemotherapy plus tislelizumab followed by radiotherapy-based, bladder-preserving treatment for high risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).

Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC): Interim analysis of ANTICIPATE phase II trial.

Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer.